TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF U.S. ADVANCED WOUND CARE MARKET 12
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 U.S. ADVANCED WOUND CARE MARKET: GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 CURRENCY AND PRICING 17
2.5 DBMR TRIPOD DATA VALIDATION MODEL 18
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 21
2.7 DBMR MARKET POSITION GRID 22
2.8 DBMR VENDOR SHARE ANALYSIS 23
2.9 MULTIVARIATE MODELING 24
2.10 PRODUCTS LIFELINE CURVE 25
2.11 SECONDARY SOURCES 26
2.12 ASSUMPTIONS 26
3 MARKET OVERVIEW 27
3.1 DRIVERS 29
3.1.1 RAPID GROWTH IN THE GERIATRIC POPULATION 29
3.1.2 INCREASING NUMBER OF ROAD ACCIDENTS AND TRAUMA INJURIES 30
3.1.3 DEVELOPMENTS AND INNOVATIONS OF NEW PRODUCTS 31
3.1.4 INCREASING SURGICAL PROCEDURES 32
3.2 RESTRAINTS 32
3.2.1 RISK ASSOCIATED WITH PRODUCTS 32
3.2.2 HIGH COST 33
3.3 OPPORTUNITIES 34
3.3.1 STRATEGIC INITIATIVES OF THE MARKET PLAYERS 34
3.3.2 POTENTIAL APPLICATION OF STEM CELL THERAPY IN WOUND CARE 34
3.3.3 INCREASING RESEARCH IN THE FIELD OF ADVANCED WOUND CARE 35
3.4 CHALLENGES 36
3.4.1 PRODUCT RECALLS 36
4 EXECUTIVE SUMMARY 37
5 PREMIUM INSIGHTS 39
6 REGULATORY SCENARIO 40
7 U.S. ADVANCED WOUND CARE MARKET, BY PRODUCT TYPE 41
7.1 OVERVIEW 42
7.2 DRESSINGS 44
7.2.1 FILM DRESSINGS 45
7.2.1.1 TRANSPARENT 45
7.2.1.2 NON TRANSPARENT 45
7.2.2 FOAM DRESSINGS 46
7.2.3 HYDROGELS 46
7.2.4 ALGINATES 46
7.2.5 WOUND CONTACT LAYER 46
7.2.6 SUPER ABSORBENT DRESSING 46
7.3 BIOLOGICS 47
7.3.1 ALLOGRAFTS 47
7.3.1.1 HUMAN DERMAL LAYER 47
7.3.1.2 CULTURED ALLOGRAFTS 47
7.3.2 SYNTHETIC SKIN GRAFTS 48
7.3.3 XENOGRAFTS 48
7.3.4 GROWTH FACTORS 48
7.3.4.1 PLATELET DERIVED GROWTH FACTOR (PDGF) 49
7.3.4.2 PLATELET RICH PLASMA (PRP) 49
7.3.4.3 EPIDERMAL GROWTH FACTORS (EGF) 49
7.3.4.4 BASIC FIBROBLAST GROWTH FACTORS (BFGF) 49
7.3.4.5 GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) 49
7.3.4.6 TALACTOFERRIN ALFA 49
7.3.4.7 THROMBIN PEPTIDE (TP508) 49
7.3.4.8 KERATINOCYTE GROWTH FACTOR (KGF) 49
7.4 THERAPY DEVICES 50
7.4.1 NEGATIVE PRESSURE WOUND THERAPY (NPWT) 50
7.4.2 U.S NEGATIVE PRESSURE WOUND THERAPY (NPWT) IN 50
7.4.2.1 PORTABLE NPWT DEVICES 51
7.4.2.2 DISPOSABLE NPWT DEVICES 51
7.4.2.3 Standalone NPWT Devices 51
7.4.3 PRESSURE RELIEF DEVICES 51
7.4.3.1 MATTRESS 51
7.4.3.2 BED 51
7.4.4 HYPERBARIC OXYGEN CHAMBERS 52
7.4.4.1 MONOPLACE 52
7.4.4.2 MULTIPLACE 52
7.4.4.3 TOPICAL 52
7.4.5 WOUND DEBRIDEMENT DEVICES 52
7.4.5.1 HYDROSURGICAL 53
7.4.5.2 ULTRASOUND 53
7.4.5.3 MECHANICAL 53
7.4.5.4 OTHERS 53
7.4.6 PHYSICAL THERAPIES 53
7.4.6.1 LASER THERAPY 54
7.4.6.2 ELECTRICAL STIMULATION 54
7.4.6.3 EXTERNAL SHOCK WAVE THERAPIES 54
7.4.6.4 SALINE MIST THERAPY 54
8 U.S. ADVANCED WOUND CARE MARKET, BY WOUND TYPE 55
8.1 OVERVIEW 56
8.2 SURGICAL WOUND 58
8.3 DIABETIC ULCERS 59
8.4 BURNS 59
8.5 PRESSURE ULCERS 59
8.6 VENOUS ULCERS 59
8.7 OTHERS 59
9 U.S. ADVANCED WOUND CARE MARKET, BY END USER 60
9.1 OVERVIEW 61
9.2 HOSPITALS 63
9.3 WOUND CARE CENTERS 64
9.4 AMBULATORY CENTERS 64
9.5 HOME HEALTHCARE 64
9.6 CLINICS 65
9.7 COMMUNITY HEALTHCARE 65
10 U.S. ADUANCED WOUND CARE MARKET, BY DISTRIBUTION CHANNEL 66
10.1 DIRECT TENDERS 69
10.2 RETAIL 70
11 U.S. ADVANCED WOUND CARE MARKET, COMPANY LANDSCAPE 71
11.1 COMPANY SHARE ANALYSIS: U.S. 71
?
12 COMPANY PROFILES 72
12.1 KCI LICENSING, INC.( SUBSIDIARY OF ACELITY L.P. INC ) 72
12.1.1 COMPANY SNAPSHOT 72
12.1.2 PRODUCT PORTFOLIO 72
12.1.3 RECENT DEVELOPMENTS 72
12.2 SMITH & NEPHEW 73
12.2.1 COMPANY SNAPSHOT 73
12.2.2 REVENUE ANALYSIS 73
12.2.3 PRODUCT PORTFOLIO 74
12.2.4 RECENT DEVELOPMENTS 75
12.3 MOLNLYCKE HEALTH CARE AB 76
12.3.1 COMPANY SNAPSHOT 76
12.3.2 RECENT DEVELOPMENTS 79
12.4 3M 80
12.4.1 COMPANY SNAPSHOT 80
12.4.2 PRODUCT PORTFOLIO 80
12.4.3 RECENT DEVELOPMENT 82
12.5 CONVATEC GROUP PLC 83
12.5.1 COMPANY SNAPSHOT 83
12.5.2 REVENUE ANALYSIS 83
12.5.3 PRODUCT PORTFOLIO 84
12.5.4 RECENT DEVELOPMENTS 85
12.6 MEDLINE INDUSTRIES, INC 86
12.6.1 COMPANY SNAPSHOT 86
12.6.2 PRODUCT PORTFOLIO 86
12.6.3 RECENT DEVELOPMENTS 91
12.7 ACELL, INC 92
12.7.1 COMPANY SNAPSHOT 92
12.7.2 PRODUCT PORTFOLIO 92
12.7.3 RECENT DEVELOPMENTS 93
12.8 ADVANCIS MEDICAL USA LLC 94
12.8.1 COMPANY SNAPSHOT 94
12.8.2 PRODUCT PORTFOLIO 94
12.9 ANIKA THERAPEUTICS, INC. 97
12.9.1 COMPANY SNAPSHOT 97
12.9.2 REVENUE ANALYSIS 97
12.9.3 PRODUCT PORTFOLIO 98
12.9.4 RECENT DEVELOPMENT 98
?
12.10 B. BRAUN MELSUNGEN AG 99
12.10.1 COMPANY SNAPSHOT 99
12.10.2 REVENUE ANALYSIS 99
12.10.3 PRODUCT PORTFOLIO 100
12.10.4 RECENT DEVELOPMENT 101
12.11 BAXTER 102
12.11.1 COMPANY SNAPSHOT 102
12.11.2 REVENUE ANALYSIS 102
12.11.3 PRODUCT PORTFOLIO 103
12.12 COLOPLAST GROUP 105
12.12.1 COMPANY SNAPSHOT 105
12.12.2 REVENUE ANALYSIS 105
12.12.3 PRODUCT PORTFOLIO 106
12.12.4 RECENT DEVELOPMENTS 107
12.13 INTEGRA LIFESCIENCES CORPORATION 108
12.13.1 COMPANY SNAPSHOT 108
12.13.2 REVENUE ANALYSIS 108
12.13.3 RECENT DEVELOPMENTS 112
12.14 JOHNSON & JOHNSON SERVICES, INC. 113
12.14.1 COMPANY SNAPSHOT 113
12.14.2 REVENUE ANALYSIS 113
12.14.3 PRODUCT PORTFOLIO 114
12.14.4 RECENT DEVELOPMENTS 115
12.15 MEDTRONIC 116
12.15.1 COMPANY SNAPSHOT 116
12.15.2 REVENUE ANALYSIS 116
12.15.3 PRODUCT PORTFOLIO 117
12.15.4 RECENT DEVELOPMENT 118
12.16 ORGANOGENESIS HOLDINGS INC. 119
12.16.1 COMPANY SNAPSHOT 119
12.16.2 REVENUE ANALYSIS 119
12.16.3 PRODUCT PORTFOLIO 120
12.16.4 RECENT DEVELOPMENTS 121
12.17 PAUL HARTMANN AG 122
12.17.1 COMPANY SNAPSHOT 122
12.17.2 PRODUCT PORTFOLIO 122
12.17.3 RECENT DEVELOPMENTS 127
?
13 QUESTIONNAIRE 128
14 RELATED REPORTS 134